AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02722278
Drug: Oral Testosterone Undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
Trial: NCT02722278
Drug: Axiron Testosterone Topical Solution
RxNorm normalized name: testosterone Topical Solution [Axiron]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg \< 350 ng/dL, decreased if \> 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
Trial: NCT00346359
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01290471
Drug: U3-1565
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
Trial: NCT01182285
Drug: Liothyronine Sodium
RxNorm normalized name: Liothyronine Sodium
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
Trial: NCT00841321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule orally twice a day for 12 weeks
Trial: NCT02607293
Drug: Gonal-f®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
Trial: NCT02607293
Drug: Long GnRH agonist
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
Trial: NCT03419806
Drug: Infudopa i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa.~From patient 6 and onwards:~Infudopa IntraV, at 81% of the subject's individual pre-study daily Duodopa dose, will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The i.v. morning bolus is 110% of the hourly continuous dose delivered at the rate of 60 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer IntraV). The morning dose will not exceed 24 mL, corresponding to 240 mg levodopa. The maximum daily dose levodopa during i.v. administration is not allowed to exceed 3240mg (equal to 81% of the maximum allowed daily dosage for Duodopa that is 4000 mg).
Trial: NCT03419806
Drug: Infudopa s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h.~From patient 6 and onwards:~Two infusion needles will be placed on the abdomen for the s.c. infusion of Infudopa SubC in 86% of the the subject's individual pre-study daily Duodopa dose. The intervention is given as a continuous fixed infusion rate for 16h preceded by a morning bolus dose. The s.c. morning bolus is 155% of the hourly continuous dose delivered at the rate of 80 ml/h (mixed volume rate Infudopa Active + Infudopa Buffer SubC). The morning dose will not exceed 30 mL. The maximum daily dose levodopa during s.c. administration is not allowed to exceed 3440mg (equal to 86% of the maximum allowed daily dosage for Duodopa that is 4000 mg).
Trial: NCT03419806
Drug: LCIG (Duodopa)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.~From patient 6 and onwards:~The pre-study daily Duodopa dose will be delivered over a 16-h period and administered as a continuous fixed infusion rate preceded by a morning bolus dose. The morning bolus is 110% of the hourly continuous dose delivered at the rate of 40 ml/h. The morning dose will not exceed 15 mL, corresponding to 300 mg levodopa. The maximum daily dose levodopa is not allowed to exceed 4000mg.
Trial: NCT04061772
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide injection
Trial: NCT03856294
Drug: Rikkunshito
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
Trial: NCT01504178
Drug: injection of placebo of L-Dopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: performed at D28
Trial: NCT00041210
Drug: ABVD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00041210
Drug: Stanford V regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00041210
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00578929
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle 1 or 2 sprays per nostril twice daily
Trial: NCT01670032
Drug: Experimental: CD07223 1.5 % Topical Gel BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Trial: NCT01670032
Drug: Experimental: CD07223 1.5% Topical Gel TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Trial: NCT01670032
Drug: Placebo Comparator: CD07223 vehicle gel BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Trial: NCT01670032
Drug: Placebo Comparator: CD07223 vehicle gel TID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
Trial: NCT01106586
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC/TDF 200/300 mg tablet administered orally once daily
Trial: NCT01106586
Drug: ATV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ATV administered orally once daily
Trial: NCT01106586
Drug: RTV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match RTV administered orally once daily
Trial: NCT01106586
Drug: FTC/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match FTC/TDF administered orally once daily
Trial: NCT00424476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Trial: NCT01645241
Drug: gonadotropins plus GnRH antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00694902
Drug: GSK610677
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
Trial: NCT00694902
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
Trial: NCT00422162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule by mouth
Trial: NCT05540951
Drug: VIC
RxNorm normalized name: Vicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIC Regimen (Vemurafenib/Irinotecan/Cetuximab)
Trial: NCT01429168
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 60-mg tablet orally daily
Trial: NCT01429168
Drug: Placebo for etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 60-mg tablet orally daily
Trial: NCT03529942
Drug: FX006 32 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release 32 mg FX006 IA injection
Trial: NCT00538499
Drug: Fentanyl citrate
RxNorm normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00720629
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/m\^2 intravenously (IV) on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
Trial: NCT00720629
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/m\^2 IV on Day 1 after transplant; 10 mg/m\^2 IV on Days 3, 6 and 11 after transplant.
Trial: NCT01474265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 tablets per day, oral use
Trial: NCT01474265
Drug: Nicorette TX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-15 mg per day, transdermal use (patches)
Trial: NCT04156685
Drug: Part A, Reference (D635 10/500mg, Astrazeneca)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day. Under fasting condition
Trial: NCT04156685
Drug: Part B, Reference (D635 10/500mg, Astrazeneca)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day. Under fed condition
Trial: NCT00748098
Drug: GSK1838262 Extended Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1838262 extended release tablets
Trial: NCT00748098
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01116830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally daily for 6 weeks
Trial: NCT01116830
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg daily orally for 6 weeks
Trial: NCT01116830
Drug: Standard Antipsychotic Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
Trial: NCT00238745
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02632045
Drug: LEE-011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg capsule (3x 200 mg capsules)
Trial: NCT02632045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg capsule (3x 200 mg capsules)
Trial: NCT04021277
Drug: 20 uL/kg PS101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
Trial: NCT04021277
Drug: 40 uL/kg PS101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 uL/kg PS101 and chemotherapy given for 4 cycles over 6 weeks
Trial: NCT02268526
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV q 4weeks
Trial: NCT02451553
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01075815
Drug: Recombinant follicle-stimulating hormone (rFSH)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00231166
Drug: HCD122
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01699178
Drug: Oral testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
Trial: NCT00872404
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg/3 weeks
Trial: NCT02114502
Drug: Caphosol
RxNorm normalized name: Caphosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL oral rinse four times a day from Day -9 until discharge.
Trial: NCT02114502
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by vein or mouth three times a day from Day -1.
Trial: NCT01196741
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
Trial: NCT03246919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered after delivery of the placenta
Trial: NCT02367248
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
Trial: NCT04382053
Drug: Standard of Care (SoC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoC included a variety of supportive therapies that ranged from the administration of supplementary oxygen to full intensive care support, alongside the use of antiviral treatment, convalescent plasma, corticosteroids, antibiotics or other agents.
Trial: NCT03829566
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A medication used as chemotherapy and to suppress the immune system
Trial: NCT01844063
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma.
Trial: NCT02195180
Drug: ERY001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02195180
Drug: 5-fluoro-uracil/oxaliplatin/leucovorin (folfox)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
Trial: NCT03689452
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free normal saline will be used as described in arm/group description section.
Trial: NCT00857909
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet twice a day
Trial: NCT00857909
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet twice a day
Trial: NCT00857909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00857909
Drug: Placebo and spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg twice daily
Trial: NCT00857909
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg twice daily
Trial: NCT02319304
Drug: FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arm description
Trial: NCT01379989
Drug: Pegylated Lipoxomal Doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 30 mg/m² i.v.
Trial: NCT02057367
Drug: Scalp block with 0.5% plain Marcaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
Trial: NCT02556918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One pill daily starting one day prior to surgery until discharge from the hospital.
Trial: NCT02556918
Drug: Regular Human Insulin
RxNorm normalized name: insulin, regular, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Trial: NCT02057367
Drug: Scalp block with 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior scalp block will be done by using 0.9% normal saline 20 ml.
Trial: NCT00747149
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT01191450
Drug: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg
RxNorm normalized name: chlorthalidone 25 MG
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
Trial: NCT01191450
Drug: Higroton® Laboratório Novartis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
Trial: NCT01513447
Drug: Intracutaneous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
Trial: NCT01905371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01537120
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01346826
Drug: Standard 2 hours-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7.
Trial: NCT01276509
Drug: PF-00547659 SC injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo delivered SC, 3 doses separated by 4 weeks
Trial: NCT01276509
Drug: PF-00547659 SC injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
Trial: NCT01276509
Drug: PF-00547659 SC injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
Trial: NCT01276509
Drug: PF-00547659 SC injection
RxNorm normalized name: taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
Trial: NCT02228083
Drug: Lidocaine with epinephrine
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
Trial: NCT01034683
Drug: lobaplatin , 5-FU ,leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
Trial: NCT00755716
Drug: Placebo (sugar pill)
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients receive
Trial: NCT02101554
Drug: Ages 7-11
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.